Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Erasca Inc (NQ: ERAS )

2.840 +0.030 (+1.07%)
Streaming Delayed Price Updated: 12:20 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 327,797
Open 2.850
Bid (Size) 2.840 (47)
Ask (Size) 2.850 (21)
Prev. Close 2.810
Today's Range 2.798 - 2.880
52wk Range 1.510 - 3.450
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ERAS Stock Earnings: Erasca Misses EPS for Q2 2024
ERAS stock results show that Erasca missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
Via Benzinga

Performance

YTD
+30.88%
+30.88%
1 Month
-11.53%
-11.53%
3 Month
+14.52%
+14.52%
6 Month
+19.33%
+19.33%
1 Year
+8.81%
+8.81%

More News

Read More
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
ERAS Stock Earnings: Erasca Misses EPS for Q1 2024
Via InvestorPlace
ERAS Stock Earnings: Erasca Beats EPS for Q4 2023
Via InvestorPlace
Why Shares of Erasca Are Jumping Tuesday
Via The Motley Fool
Erasca Reports First Quarter 2024 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Erasca Announces $45 Million Oversubscribed Private Placement Financing
From Erasca, Inc.
Via GlobeNewswire
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
From Erasca, Inc.
Via GlobeNewswire
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
From Erasca, Inc.
Via GlobeNewswire
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Erasca, Inc.
Via GlobeNewswire
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Erasca, Inc.
Via GlobeNewswire
3 Penny Stocks You’ll Regret Not Buying Soon: December Edition
Via InvestorPlace
RiskOn International And 3 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
From Erasca, Inc.
Via GlobeNewswire
$1.7M Bet On Erasca? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
From Erasca, Inc.
Via GlobeNewswire
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
From Erasca, Inc.
Via GlobeNewswire
Erasca to Present at Upcoming Investor Conferences in November
From Erasca, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.